| UPDATED: 10:41, Wed, Dec 16, 2020
Link copied Sign up for FREE now and never miss the top Royal stories again.
SUBSCRIBE Invalid email
When you subscribe we will use the information you provide to send you these newsletters.
Sometimes they ll include recommendations for other related newsletters or services we offer.
Our Privacy Notice explains more about how we use your data, and your rights.
You can unsubscribe at any time.
Princess Delphine, who spent years battling for recognition as the child of Belgium s former King Albert II, has launched the Princess Delphine of Saxe-Coburg Fund, a scheme promoting the use of art in health care. She has also been appointed honorary chair of this fund, the work of which perfectly combines Princess Delphine s desire to use her new title to do good with her career as an artist.
Luc Van Braekel/CC/Flickr
Princess Delphine has shared her name with a cultural fund to support arts in health care, with the creation of the Princess Delphine of Saxe-Coburg Fund.
Created by the Ghent University Hospital, Princess Delphine’s fund will promote the healing power of art and will support initiatives like “scientific research into the impact of art in healthcare, training and awareness-raising initiatives about art in healthcare, workshops, concerts, lectures…in collaboration with external partners in the arts…” as well as “infrastructural projects such as the artistic design of multipurpose spaces, purchase and rental of equipment for workshops, artworks,” and “the development or purchase of software to enable artistic initiatives,” the Hospital’s website explains.
E-Mail
Phase 2 trials in 1,200 adults, young children, and infants suggest new poliovirus vaccine may have the potential to overcome outbreaks caused by a mutated polio strain linked to the oral vaccine that typically circulates in areas of low immunisation coverage, and poses one of biggest barriers to eradication.
Scientists have developed the first poliovirus vaccine against a mutated form of the disease that is causing disease outbreaks across Africa and Asia. Designed to be more genetically stable than the licensed Sabin oral vaccine [1], the new vaccine appears to be as safe and provides similar immune responses when tested in healthy adults, children, and infants, according to new research published in two papers in